Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  asparaginase
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 25 for your search:
Start Over
Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses
Phase: Phase IV
Type: Treatment
Status: Active
Age: 1 to 14
Sponsor: Other
Protocol IDs: 2005-000658-56, 20040177, 2004-41-4276, NCT00192673
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991
LAL-BR/2001: Study Treatment to Low Risk ALL
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 and under
Sponsor: Other
Protocol IDs: LAL-BR/2001, NCT00526175
Treatment of High Risk Adult Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: LAL-AR/2003, NCT00853008
Treatment of Natural Killer/T Cell Lymphoma-?/?
Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011-2, NCT01501149
Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 6 months to 18 years
Sponsor: Other
Protocol IDs: CCALL2012, NCT01990807
Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 30
Sponsor: Other
Protocol IDs: LAL-RI/2008, NCT02036489
High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
Phase: Phase III
Type: Treatment
Status: Active
Age: 25 to 65
Sponsor: Other
Protocol IDs: JALSG ALL202-O, NCT00131027
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: CDR0000613220, MOTOL-ALL-IC-BFM-2002, EU-20871, ALL-IC-BFM-2002, NCT00764907
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 18
Sponsor: Other
Protocol IDs: AIEOP-BFM ALL 2009, NCT01117441
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA180886, U10CA098543, NCT01371981
Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 18
Sponsor: Other
Protocol IDs: POWH-CRE-2008.077-T, CDR0000595184, NCT00707083
Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:
Phase: Phase III
Type: Treatment
Status: Active
Age: 14 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: ChangzhouJP, NCT02070523
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 24
Sponsor: Other
Protocol IDs: JALSG ALL202-U, NCT00131053
Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2006-0328, NCI-2012-01518, NCT00501826
New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 14 to 75
Sponsor: Other
Protocol IDs: LMTG 09-02, NCT00933673
Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-04-033, NCT01007526
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0598, NCI-2011-00861, NCT01319981
Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2010-0708, NCI-2011-01061, NCT01363128
Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: KALLA0804, NCT01429610
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Phase: No phase specified
Type: Treatment
Status: Active
Age: 365 days and under
Sponsor: Other
Protocol IDs: CDR0000570260, DCOG-INTERFANT-06, EUDRACT-2005-004599-19, CCLG-LK-2006-10, NCT00550992
Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008
Phase: No phase specified
Type: Natural history/Epidemiology
Status: Active
Age: 1 to 16
Sponsor: Other
Protocol IDs: ASP NOPHO 2008, NCT00982514
Pharmacokinetics of Asparaginase and Antibody Formation in Interfant-06
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Status: Active
Age: 1 and under
Sponsor: Other
Protocol IDs: Interfant-06, NOPHO, register identifier, NCT01025804
Hemostasis During Asparaginase Treatment in Acute Lymphoblastic Leukemia(ALL)
Phase: No phase specified
Type: Natural history/Epidemiology
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: Hemostasis-NOPHO, NCT01094392
Multicenter Clinical Trial for Adult Ph-negative ALL. Continuous Treatment With Modification of Cytostatic Drugs Doses Depending on Myelosuppression Severity
Phase: No phase specified
Type: Treatment
Status: Active
Age: 15 to 55
Sponsor: Other
Protocol IDs: ALL-2009, NCT01193933
Start Over